Kainic acid-induced seizures in the common marmoset.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
07 05 2020
Historique:
received: 23 01 2020
accepted: 20 02 2020
pubmed: 3 3 2020
medline: 5 11 2020
entrez: 3 3 2020
Statut: ppublish

Résumé

Treatment of epilepsy remains difficult because patients suffer from pharmacoresistant forms of the disease and drug side-effects. Thus, there is an urgent need to identify not only new antiepileptic drug candidates but also novel epileptic animal models. Here, we characterize seizures induced with kainic acid (KA) in the common marmoset (Callithrix jacchus). Adult marmosets received 0.1, 1, or 10 mg/kg of KA subcutaneously. All animals exhibited early convulsive behavior (seizure scores of I and II on the Racine scale). Seizure scores were low at lower KA doses, but the highest dose of KA tested triggered generalized seizures (scores IV and V on the Racine scale). We next performed preliminary evaluation of the efficacy of the antiepileptic drug diazepam. This drug at 1 mg/kg (delivered subcutaneously) prevented 10 mg/kg KA-induced stage V seizures. KA administration to marmosets reliably triggers generalized seizures; therefore, the marmoset is a useful animal model in which to analyze the seizures of a nonhuman primate brain and to develop new treatments for epilepsy.

Identifiants

pubmed: 32115153
pii: S0006-291X(20)30402-2
doi: 10.1016/j.bbrc.2020.02.121
pii:
doi:

Substances chimiques

Diazepam Q3JTX2Q7TU
Kainic Acid SIV03811UC

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

595-599

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Akiyoshi Ishikawa (A)

Sleep Science Laboratories, HAMRI Co. Ltd, Ibaraki, 306-0128, Japan.

Yuri Mizuno (Y)

Sleep Science Laboratories, HAMRI Co. Ltd, Ibaraki, 306-0128, Japan.

Keita Sakai (K)

Sleep Science Laboratories, HAMRI Co. Ltd, Ibaraki, 306-0128, Japan.

Takehiro Maki (T)

Sleep Science Laboratories, HAMRI Co. Ltd, Ibaraki, 306-0128, Japan.

Ryo Tanaka (R)

Sleep Science Laboratories, HAMRI Co. Ltd, Ibaraki, 306-0128, Japan.

Yasuhiro Oda (Y)

Sleep Science Laboratories, HAMRI Co. Ltd, Ibaraki, 306-0128, Japan.

Kimie Niimi (K)

Research Resources Division, RIKEN Center for Brain Science, Saitama, 351-0198, Japan. Electronic address: kimie.niimi@riken.jp.

Eiki Takahashi (E)

Research Resources Division, RIKEN Center for Brain Science, Saitama, 351-0198, Japan. Electronic address: eiki.takahashi@riken.jp.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH